News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$SIPC Sipp Industries Secures Partnership with Brewery for Enhanced Production Capacity and Provides Update on Hemp Beer
www.sippindustries.com. Facebook: https://www.facebook.com/SippIndustries Twitter: @SippIndustries
https://www.facebook.com/SippIndustries/
Sipp Industries Secures Partnership with Distinguished Brewery for Enhanced Production Capacity and Provides Update on Hemp and CBD Beer Initiatives
COSTA MESA, CA -- October 20, 2016 -- InvestorsHub NewsWire -- Sipp Industries, Inc. (OTC: SIPC), a multifaceted corporation specializing in technology, manufacturing, and distribution of commercial and consumer products is pleased to announce the Company has entered into a contractual agreement with a notable Colorado brewery. In anticipation of rising demand upon licensing, the Company has mobilized to strengthen the Companys production capacity.
2016 has, thus far, been a very productive and transformational year for Sipp Industries. Having initially entered the market as a bulk hemp ingredient supplier to various product manufacturers and local Colorado craft breweries, such as Crazy Mountain Brewing and Ute Pass Brewing Co., Management discerned very quickly that the Company was standing at the threshold of an immense opportunity. In recognition of the potential market for distinctly formulated hemp infused beer, the Company decided to embark on the formulation, manufacturing and distribution of an exclusive line of hemp and Cannabidiol (CBD) beer.
The Companys strong prospect for success was discovered at a successful 4/20 event at Ute Pass Brewing Co. where patrons and shareholders sampled five distinct varieties of hemp and CBD beer. After receiving favorable reviews for its exceptional taste, subsidiary Major Hemp mobilized to determine and execute the best strategy to take this initiative to the next level, which involved interaction with potential licensing parties, manufacturing partners, and distributors.
Over the past quarter, the Company has become keenly aware of the advantages of exclusive ownership of its hemp and CBD recipes, trademarks, and wholesale licenses. By moving to secure the Companys proprietary rights, Sipp Industries takes full control of its own destiny as the business expands. As terms are finalized with legal counsel, Sipp Industries will establish full proprietary rights and control of the Companys hemp and CBD beer recipes. The Company expects to be able to make a formal announcement by the end of the month.
The Companys secondary hemp beer initiative focal point is the establishment of increased production capacity. In order to meet the demand requirements of major beer distributors, the company must prove it can consistently fulfill large orders. Major Hemp President Ted Jorgensen stated: In anticipation of the fact that we had to be prepared to meet a quickly growing demand, we have been proactive in the search for capable partners. After interviewing multiple prospects, we have selected a brewer that exceeds all of our expectations and requirements.
This brewery, soon to be announced as partner, maintains a 70,000 square foot facility just outside Denver and has the capacity to produce up to 200,000 barrels a year. Moreover, this manufacturer is located in the heart of the Denver craft brew scene, which will bolster brand awareness and keep transportation costs down. This new partner also has access to local and national distributors which will enable Sipp Industries with the benefit of full turnkey brewing and distribution capabilities.
Chief Executive Officer Syman Vong commented, We are confident that the time and effort invested into the creation and licensing of our proprietary hemp-infused and CBD beer will result in great success for the company and its shareholders. He concluded: We firmly believe that the greatest potential for a high level of success is when timing and opportunity meet. At this stage in the game in the industry, its evident that the revenue potential here can be exponential.
Upon finalization of all licensing and manufacturing agreements, the Company plans to update shareholders with an anticipated timeline for availability and its first wholly-owned hemp beer run.
About Sipp Industries, Inc.
Sipp Industries is a multifaceted corporation that specializes in technology, manufacturing and distribution of commercial and consumer products. Through its wholly owned subsidiary, Major Hemp, the Company provides high quality and competitively priced hemp based products, bulk hemp, CBD supply, co-packing and private labeling services.
Website: http://www.sippindustries.com.
Facebook: https://www.facebook.com/SippIndustries
Twitter: @SippIndustries
Forward Looking Statements:
This release contains forward-looking statements within the meaning of Section 27a of the Securities Act of 1933, as amended and section 21e of the Securities and Exchange Act of 1934, as amended. Those statements include the intent, belief or current expectations of the company and its management team.
Forward-looking statements are projections of events, revenues, income, future economics, research, development, reformulation, product performance or management's plans and objectives for future operations. Some or all of the events or results anticipated by these forward-looking statements may not occur. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. Accomplishing the strategy described herein is significantly dependent upon numerous factors, many that are not in management's control.
Contact:
Ted Jorgensen
Major Hemp President
Sipp Industries, Inc.
Investor Relations
ir@sippindustries.com
949.220.0435
$SIPC We're working on a line of products that your horses are going to love. Please stay tuned.
www.sippindustries.com. Facebook: https://www.facebook.com/SippIndustries Twitter: @SippIndustries
https://www.facebook.com/SippIndustries/
$PMCB Cardica News and Response Bodes Well for Pharmacyte Biotech
Cardica, Inc. (NASDAQ:CRDC) has given the market a not-so-gentle reminder that biotechnology and medical devices aren't under the same fire as biopharmaceuticals. Time to put Pharmacyte Biotech Inc. (OTCMKTS:PMCB) back on the radar, for the same reason.
After more than a year's worth of miserable performance from the stock, Cardica, Inc. (NASDAQ:CRDC) shares are soaring, up 36% today on the heels of news that its surgical stapling device has been cleared by the FDA for far more uses than had been previously permitted. The news doesn't come as a complete shock to CRDC owners, though that's certainty didn't start to materialize until after January 7th when the company announced a new partnership agreement with Intuitive Surgical that vaguely suggested good news was on the way. And, even the inkling of good news didn't do as much for Cardica shares as the confirmed news did this morning.
In a bigger sense, while pharmaceuticals and specialty drugs were under fire during the latter half of 2015, that weakness also unfairly pressured makers of biotech devices lower. The rebound from CRDC helps to imply the group is in rebound mode now, so for investors looking to pick up other compelling but speculative biotech device ideas may want to add Pharmacyte Biotech Inc. (OTCMKTS:PMCB) if not their portfolio.
Pharmacyte Biotech is the developer of a biotechnology called Cell-In-a-Box, which is making the healthcare industry rethink what's possible in terms of drug delivery.
Pharmacyte Biotech has, in simplest terms, perfected the elusive art of live cell encapsulation. In other words, PMCB is successfully doing what most researchers and biotech companies have struggled to do well (and been unable to do for the long haul) by encapsulating live cells in a package that (1) is small enough to be implanted into a human body, (2) durable enough to resist a body's immune response, and (3) porous enough to allow the healthy cells living inside the encapsulation to operate normally when that patient's own cells aren't doing their job. Cell-in-a-Box is that biotechnology.
It's as much of a process as it is a molecular structure. The first step in their creation is a mix of live cells (that ultimately spur or even become the therapy) and a proprietary polymer that is then dropped into another proprietary polymer. The two polymers react to form a solid object about the size of the head of the pin, with the still-living cells beneath the shell of the tiny sphere. Though only a few millimeters across, the number of living cells inside the tiny bead-sized capsule can be in the thousands.
While it's not a new idea, Pharmacyte has upped the ante, so to speak, on encapsulation. These capsules allow the cells inside to receive nutrients from a body as well as emit certain chemicals, yet they don't let antibodies in and potentially kill the outside, unrecognized cells the way an immune system normally would. And, unlike most other encapsulation efforts, the capsule itself isn't known to degrade.
The implications for such a technology are almost limitless, although Pharmacyte is first focusing on two arenas... pancreatic cancer, and type 1 diabetes.
On the diabetes front, the cells "in the box" would be insulin-producing engineered Magellan cells inside the pinhead-sized beads, which are then surgically deposited in the leg, near the bloodstream. Just like a patient's own cells would detect the presence of glucose and begin producing insulin, the cells inside the encapsulation are capable of sensing high levels of glucose and produce an appropriate amount of insulin.
As for pancreatic cancer, Cell-in-a-Box is a means of placing thousands of live cells that produce a P450 enzyme inside the capsule, which can activate an otherwise inactive form of cancer drug ifosfamide to produce an anti-cancerous effect.
The upside to this approach is pin-point placement.
Ifosfamide in its active form is usually delivered intravenously and then activated in the liver. The process "works", but much of the drug doesn't make it to the pancreas. To deliver a dose big enough to make a dent in a pancreatic tumor, nasty side effects are almost a given. The Cell-in-a-Box approach circumvents this inefficient form of delivery by inserting encapsulated P450-producing cells very near the tumor itself, which means ifosfamide isn't activated until it's at or near the pancreatic tumor, which means the bulk of the drug is delivered where it needs to be delivered. This in turn means less of the drug is necessary to produce a response. Less of a drug means fewer side effects, without giving up efficacy.
It blurs the line between biotechnology device and biopharmaceuticals... as most next-generation treatments should.
Though there's still more work to be done, as most veteran traders can attest, the market rewards biotech companies reaching milestones by pushing the stock upward. The PMCB premise alone already has plenty of people interested, and with 2016 being a year with lots of catalysts in the queue, now's the time to start taking a closer look.
With that in mind, just this morning the company updated its explanation of its biotechnology and added some new information about Cell-In-a-Box. Newcomers as well as those familiar with Pharmacyte Biotech will want to take a look right here.
http://money.cnn.com/news/newsfeeds/articles/globenewswire/6150096.htm
|
Followers
|
66
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1463
|
|
Created
|
12/09/15
|
Type
|
Premium
|
| Moderators | |||
